全部期刊

—

	期刊 Title	FREE	SCIE SSCI AHCI ESCI EI Scopus MEDLINE CSCD 科技核心中信所世界一流 Q1 Q2 Q3 Q4 1区 2区 3区 4区 TOP 1区 2区 3区 4区 TOP A* A B C ABS 4* 4 3 2 1 免费发表 OA DOAJ 中科院预警中信所预警 Under Review On Hold	IF ▼	审稿周期

AILatestJournal

AILatest Journal — 面向科研人员的期刊检索与投稿决策工具，聚合 SCI/SSCI、中科院分区、JCR、ESI、CSSCI、北大核心、浙大目录等数据，支持收藏、评分与跨设备同步。

JCR 分区

Q1 Q2 Q3 Q4

ABDC

A* A B C

学科 / 研究主题 (WoS + OpenAlex)

期刊详情

中文版 →

Journal details

CANCER BIOLOGY & MEDICINE

CHINA ANTI-CANCER ASSOC · ISSN 2095-3941 · eISSN 2095-3941

Oncology

SCIEScopusMEDLINEPubMedPMCDOAJ

Official website Open interactive view Journal warning lists

Overview

CANCER BIOLOGY & MEDICINE is a Oncology · Medicine, Research & Experimental journal published by CHINA ANTI-CANCER ASSOC (Peoples R China). Use this page to check its impact factor, JCR quartile, CAS zone and indexing before you submit. Always confirm the scope, APC and policies on the journal's official website.

Impact factor (2025)

12.4

JIF without self-citations

12.3

Self-citation share

0.81%

JCR quartile

CAS zone

Zone 2

Publisher

CHINA ANTI-CANCER ASSOC

Country / region

Peoples R China

Publication output

2026: 87 articles · 2025: 120 articles · 2024: 85 articles. Source: OpenAlex open data.

Related journals

BIOMARKER RESEARCH IF 14.6 · Q1
CLINICAL AND TRANSLATIONAL MEDICINE IF 7.9 · Q1
MOLECULAR MEDICINE REPORTS IF 5 · Q2
MELANOMA RESEARCH IF 1.8 · Q3
MOLECULAR THERAPY ONCOLOGY IF 8.5 · Q1
CANCER AND METASTASIS REVIEWS IF 12.7 · Q1
CANCER LETTERS IF 11.8 · Q1
MOLECULAR THERAPY IF 11.4 · Q1

FAQ

What is the impact factor of CANCER BIOLOGY & MEDICINE?

The impact factor recorded for CANCER BIOLOGY & MEDICINE is 12.4 (2025 JCR release), JCR quartile Q1.

What is the CAS zone (Chinese Academy of Sciences ranking) of CANCER BIOLOGY & MEDICINE?

CANCER BIOLOGY & MEDICINE is listed in CAS Zone 2.

Which databases index CANCER BIOLOGY & MEDICINE?

CANCER BIOLOGY & MEDICINE is indexed in SCIE, Scopus, MEDLINE, PubMed, PMC, DOAJ. Confirm on the journal website and the database itself before submitting.